

Urodynamic and clinical evaluation of postmenopausal women with stress urinary incontinence before and after cyclic estrogen therapy

V. R. V. Góes, M. G. F. Sartori, E. C. Baracat, G. Rodrigues de Lima, M. J. B. C. Girão

Gynecology Department, Federal University of São Paulo (Brazil)

Summary

Objective: The purpose of this study was to evaluate the effects of isolated cyclic estrogen therapy in menopausal women with stress urinary incontinence, and thus without the effects of progesterone.

Methods: Nineteen menopausal patients with stress urinary incontinence were selected and submitted to anamnesis and physical, gynecological and urodynamic examinations. The group was homogeneous in relation to parity, body mass index and degree of urogenital prolapse. All the patients received conjugated equine estrogens orally, at a dose of 0.625 mg, for 21 days each month. After three months the clinical and urodynamic evaluations in relation to urine loss, were performed again.

Results: Of the patients 57.9% were satisfied with the treatment. The urodynamic parameters remained unaltered in 36.85% of the patients.

Conclusion: Our results show that estrogen is important for stress urinary incontinence in postmenopause, specially in patients without cystocele or with cystocele of degree I or II.

Key words: Urinary incontinence; Estrogen replacement; Urodynamic.

Introduction

With the increase in life expectancy women are living around a third or more of their lives after menopause, and are therefore submitted to the prejudicial effects of estrogen deprivation for a substantial part of their lives. Of these effects those on the urinary tract, and in particular urinary incontinence stand out [1, 2].

The bladder and proximal urethra have endodermic origins, while the bladder trigone, formed from the mesonephric duct, has mesodermic origins [3]. Thus, the vagina and distal urethra originate from the urogenital sinus and therefore, steroids, and in particular estrogen receptors have been found in both [4].

Hormonal receptors have been identified in the lower urinary tract and in the pelvic musculature [3, 5], and the action of estrogens on the alphaadrenergic receptors found in the periurethral musculature, increase their number and sensitivity [6, 7].

There are various factors necessary for the maintenance of urinary continence, but prominent among them are the integrity of the urethral sphincter system, neck of the bladder and the proximal urethra [8].

The results of estrogen therapy on postmenopausal urogenital alterations are controversial, since the evaluation criteria, the types of hormones employed, the routes of administration and the dosages are widely varied [9, 10].

Thus various clinical studies have concluded that women with urinary symptoms such as dysuria, urgency and incontinence, when treated with estrogens present considerable improvement during the estrogen replacement [11, 12]. However, neither Wilson *et al.* [13] nor Cardozo [14] could confirm this finding.

Through the use of urodynamic studies it is possible to obtain more objective diagnostic data which permit more adequate comparisons of the various treatments [14]. It has been observed that, with the advancement of age, there is a significant drop in the urethral closing pressure, a smaller bladder capacity and an increase in the post-micturition residue [15-17].

An increase in the urethral pressure profile after hormone replacement was observed in women treated either orally or vaginally with estrogens [18].

Sartori *et al.* [10] observed that oral estrogen and progesterone therapy, in post-menopausal women with stress urinary incontinence, promoted significant clinical improvement, as well as increasing the bladder capacity, the average urinary flow and the maximum closing pressure of the urethra.

In relation to the progesterones, Raz *et al.* [19] noted that their administration in female dogs caused stimulation of the beta-adrenergic receptors of the urethra and a consequent reduction in urethral pressure. However Rud [20] did not observe these alterations in humans.

Although the urodynamic results of hormone replacement in the treatment of stress urinary incontinence in postmenopause have not been uniform, the symptoms have improved in a great majority of studies [10, 18].

Therefore, various authors have sought to analyze the alterations that occur in the urethral mucosa and in the periurethral vascularization, musculature connective tissue after the use of steroid hormones, which could contribute to postmenopausal urinary continence [20].

Suguita *et al.* [21] observed that estrogen replacement in castrated rats, whether or not associated with progesterone, promoted metaplasia, hyperplasia and an increase in the thickness of the lower urinary tract epithelium.

Revised manuscript accepted for publication August 26, 2002

The large periurethral blood vessels, disproportionate to the need to supply blood to the urethra, form a type of spongy body with an erectile function [22], through which intravascular pressure is transmitted mechanically to the urethra, obstructing it and impeding, in this way, the loss of urine. This vascular plexus is influenced by estrogen, which not only increases the passage of blood to the urethral cells, but also the arterial pulse [19]. However, progesterone reduces the effects observed with estrogens [23].

Endo *et al.* [24] observed that isolated estrogens increased the count of bladder and urethra blood vessels in castrated adult rats in relation to a group which only received placebo. However, association with progesterones also increased the number of blood vessels, although to a lesser extent.

Jármy-Di Bella *et al.* [25], used digitized color-Doppler velocimetry to study the periurethral blood vessels of fertile and postmenopausal women with and without stress urinary incontinence. They showed that the number of periurethral blood vessels, the systolic peak and diastolic minimum were less in the incontinent women after menopause, with a high incidence of a final diastole of zero, reflecting a high resistance to blood flow and therefore difficulty in carrying blood to the areas irrigated by these vessels.

Girão *et al.* [26] showed that estrogen replacement increased the number of periurethral blood vessels, systolic peak and diastolic minimum, with a tendency to reduce vascular resistance.

It has been shown that there are estrogen and androgen receptors in the skin fibroblasts which suggests that these collagen producing cells are susceptible to these hormones. On the other hand, a significant correlation was found between the quantity of collagen in the skin and the function of the urethral sphincter, confirming that estrogen therapy in postmenopause improves the urethral function due to an increase in the quantity of collagen in the urogenital tissues [27, 28].

Analysis of the quantity of muscle fibers and collagen on the urethral musculature of castrated rats that receive estrogen, medroxyprogesterone acetate or both, has shown that isolated estrogen replacement favors a reduction in infiltrated collagen in the muscles. However, it induces a significant increase in the muscle fibers while progesterone does the opposite. Thus, the administration of progesterone does not appear to be ideal for improving the muscle layer of the urethra during hypoestrogenism [29].

As there are still questions regarding hormone replacement for the treatment of stress urinary incontinence, the present study was performed to evaluate the effects of isolated cyclic estrogen therapy in menopausal women with stress urinary incontinence, and thus without the effects of progesterones.

Materials and Methods

Nineteen menopausal patients with stress urinary incontinence were selected and submitted to anamnesis and physical, gynecological and urodynamic examinations.

The study did not include women with urinary infections, neurological illnesses, kidney diseases, serious hepatic diseases,

severe arterial hypertension, immunological illnesses or any women who presented contraindications to the use of estrogens, such as hormone dependent cancer or prior thromboembolic diseases.

Included in the study were patients with a history of more than a year of stress urinary incontinence, who were not using hormone replacement. The group was homogeneous in relation to parity, body mass index and degree of urogenital prolapse.

All the patients received conjugated equine estrogens orally, at a dose of 0.625 mg, for 21 days each month. After three months the clinical and urodynamic evaluations in relation to urine loss, were performed again.

The subjective evaluation, performed by the patients, was counted as a cure when there were no more episodes of urine loss; as a marked improvement when urine loss continued, although more rarely, and the patient was satisfied with the treatment and was not interested in other therapies; as an improvement when there was a reduction in the episodes of urine loss but not sufficient to satisfy the patient; and as unaltered when there was no improvement whatsoever.

The objective evaluation was performed by a urodynamic examination.

The standard t-test was employed for statistical analysis with p set at 0.05 or 5%.

Results

Of the patients 57.9% were satisfied with the treatment, reporting either a cure or a marked improvement (Figure 1). There were, however, no significant alterations in the urodynamic data (Table 1).

Nevertheless, four (21.05%) of the women were no longer losing urine in the urodynamic evaluation performed after three months and in eight (42.10%) loss continued but with a greater bladder volume. The urodynamic parameters remained unaltered in 36.85% of the patients (Table 2).




Figure 1. — Subjective evaluation of urine loss three months after treatment.

Table 1. — Urodynamic data before and three months after cyclic estrogen treatment.

Urodynamic data	Before	After
Post-micturition residue	8.6 ml	10.5 ml
Bladder capacity at first desire to void	132.5 ml	178.9 ml
Maximum cystometric capacity	413.2 ml	413.2 ml
Maximum urethral closing pressure	51.9 cmH ₂ O	52.4 cmH ₂ O
Functional length of the urethra	2.0 cm	2.3 cm
Maximum urinary flow	24.8 ml/s	27.5 ml/s
Average urinary flow	14.6 ml/s	15.9 ml/s

Table 2. — Bladder volume (ml) at the moment of urine loss, before and after cyclic estrogen treatment.

Patient number	Before	After
1	200	300
2	200	200
3	No loss	No loss
4	350	No loss
5	200	No loss
6	200	400
7	300	400
8	No loss	No loss
9	No loss	No loss
10	No loss	450
11	No loss	No loss
12	200	200
13	No loss	No loss
14	No loss	No loss
15	250	500
16	300	450
17	500	300
18	200	200
19	200	No loss

Discussion

As urinary incontinence in postmenopause can be caused or aggravated by hypoestrogenism, this study sought to investigate the role of estrogens in its treatment. To this end the effects of cyclical estrogen replacement in postmenopausal women with stress urinary incontinence were evaluated, both through subjective data reported by the patients, and through objective data collected during urodynamic examinations.

Our results showed that 57.9% of the patients were satisfied after the hormone therapy, and did not want other forms of therapy. However, 42.1% judged their situation to be only a little better or unaltered following the hormone therapy.

These findings are in agreement with those of various other studies [9-12] which have clearly shown the beneficial effects of estrogen therapy on incontinent women in the post-menopause.

The urodynamic results reflected clinical improvement. In 24.05% of the women urine loss was no longer observed during cystometry. In 42.10% of the cases, loss did occur but only with a bladder volume greater than that before the start of treatment (Table 2). Thus a group of women themselves to be cured or improved, but continue to have objective urine loss although with a greater bladder volume. These data suggest that such patients feel that they are cured because they do not reach their new bladder volume during their daily routine and therefore no longer present episodes of urine loss.

The treatment did not result in any statistically significant difference in the urethral profile. These results are in agreement with those in the literature [18].

In relation to the functional length of the urethra, it was not possible to show any alterations after three months of hormone treatment, similar to other studies [10, 15].

Our results show that estrogen is important for stress urinary incontinence in postmenopause, specially in patients without cystocele or with cystocele of degree I or II.

References

- [1] Bent A.E.: "Geriatric Urogynecology". In: Ostergard D.R. & Bent A.E. (eds.), "Urogynecology and Urodynamics". Baltimore, Williams & Wilkins, 1991, 518.
- [2] Baracat E.C.: "Distúrbios urogenitais da mulher menopausada: tratamento da atrofia urogenital". *J. Bras. Gynecol.*, 1992, 102, 9.
- [3] Iosif C.S., Batra S., Ek A., Astedt B.: "Estrogen receptors in the human female lower urinary tract". *Am. J. Obstet. Gynecol.*, 1981, 141, 817.
- [4] Gosling J.A., Dixon J.: "Embryology and ultrastructure of the female lower urinary tract". In: Ostergard D.R. & Bent A.E. (eds.), "Urogynecology and Urodynamics: Theory and Practice". 3rd ed. Baltimore, Williams & Wilkins, 1991, 19.
- [5] Ingelman-Sundberg A., Rosén J., Gustafsson S. A., Carlström K.: "Cytosol estrogen receptors in the urogenital tissues in stress-incontinent women". *Acta Obstet. Gynecol. Scand.*, 1981, 60, 585.
- [6] Batra S.C., Bjellin L., Sjögren C., Iosif C.S., Widmark E.: "Increases in blood flow of female rabbit urethra following low doses estrogens". *J. Urol.*, 1986, 136, 1360.
- [7] Callahan S.M., Creed K.E.: "The effects of oestrogens on spontaneous activity and responses to phenylephrine of the mammalian urethra". *J. Physiol.*, 1985, 358, 35.
- [8] Blaivas J.G., Olsson C.A.: "Stress incontinence: Classification and surgical approach". *J. Urol.*, 1988, 139, 727.
- [9] Fantl J.A., Cardozo L., McClish D.K., The Hormones and Urogenital Therapy Committee: "Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee". *Obstet. Gynecol.*, 1994, 83, 12.
- [10] Sartori M.G.F., Baracat E.C., Girão M.J.B.C., Gonçalves W.J., Sartori J.P., Rodrigues De Lima G.: "Menopausal genuine stress urinary incontinence treated with conjugated estrogens plus progestogens". *Int. J. Gynecol. Obstet.*, 1995, 49, 165.
- [11] Schleyer-Saunders E.: "Hormone implants for urinary disorders in postmenopausal women". *J. Am. Geriatr. Soc.*, 1976, 24, 337.
- [12] Molander U., Milsom I., Ekelund P., Arvidsson L., Eriksson O.: "A health care program for the investigation and treatment of elderly women with urinary incontinence and related urogenital symptoms". *Acta Obstet. Gynecol. Scand.*, 1991, 70, 137.
- [13] Wilson P.D., Faragher B., Butler B.: "Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women". *Br. J. Obstet. Gynaecol.*, 1987, 94, 568.
- [14] Cardozo L.: "Role of estrogens in the treatment of female urinary incontinence". *J. Am. Geriatr. Soc.*, 1990, 38, 326.
- [15] Diokno A.C.: "Diagnostic categories of incontinence and the role of urodynamic testing". *J. Am. Geriatr. Soc.*, 1990, 38, 300.
- [16] Wakavaichi V.M.B., Sartori M.G.F., Endo R.M., Girão M.J.B.C., Gonçalves W.J., Baracat E.C., Rodrigues De Lima G.: "Incontinência urinária de esforço no climatério: avaliação de parâmetros urodinâmicos". *Rev. Bras. Med. Ginecol. Obstet.*, 1994, 5, 442.
- [17] Sartori M.G.F., Oliveira L.M., Motta E.L.A., Girão M.J.B.C., Baracat E.C., Rodrigues De Lima G.: "Avaliação urodinâmica em mulheres na pós-menopausa com incontinência urinária de esforço segundo o tempo de menopausa". *Ginecol. Obstet. Atual.*, 1995, 6, 13.
- [18] Sacco F., Rigon G., Carbone A., Sacchini D.: "Terapia estrogenica transvaginale dell'incontinenza urinaria da sforzo". *Minerva Gynecol.*, 1990, 42, 539.
- [19] Raz S., Caine M., Zeigler M.: "The vascular component in the production of intraurethral pressure". *J. Urol.*, 1972, 108, 93.
- [20] Rud T.: "Urethral pressure profile in continent women from childhood to old age". *Acta Obstet. Gynecol. Scand.*, 1980, 59, 331.
- [21] Suguita M.A., Girão M.J.B.C., Simões M.J., Sartori M.G.F., Baracat E.C., Rodrigues De Lima G.: "A morphologic and morphometric study of the vesical mucosa and urethra of castrated female rats following estrogen and/or progestogen replacement". *Clin. Exp. Obstet. Gynecol.*, 2000, 27, 176.

- [22] Berkow S.G.: "The corpus spongiosum of the urethra: its possible role in urinary control and stress incontinence in women". *Am. J. Obstet. Gynecol.*, 1953, 65, 346.
- [23] Batra S.C., Bjellin L., Iosif C.S., Martensson L., Sjögren C.: "Effect of oestrogen and progesterone on the blood flow in the lower urinary tract of the rabbit". *Acta Physiol. Scand.*, 1985, 123, 191.
- [24] Endo R.M., Girão M.J.B.C., Sartori M.G.F., Simões M.J., Baracat E.C., Rodrigues De Lima G.: "Effects of estrogen-progesterone hormonal replacement therapy on periurethral and bladder vessels". *Int. J. Urogynecol.*, 2000, 11, 120.
- [25] Jármy-Di Bella Z.I.K., Girão M.J.B.C., Sartori M.F.G., Di Bella Júnior V., Lederman H.M., Baracat E.C., Lima G.R.: "Power Doppler of the urethra in continent or incontinent, pre- and postmenopausal women". *Int. J. Urogynecol.*, 2000, 11, 148.
- [26] Girão M.J.B.C., Jármy-Di Bella Z.I.K., Sartori M.G.F., Baracat E.C., Rodrigues De Lima G.: "Dopplervelocimetry parameters of periurethral vessels in postmenopausal incontinent women receiving estrogen replacement". *Int. Urogynecol. J.*, 2001, 12 (4), 241.
- [27] Stumpf W.E., Sar M., Joshi S.G.: "Estrogen target cells in the skin". *Experientia*, 1974, 30, 196.
- [28] Versi E., Carodozo L., Brincat M., Cooper D., Montgomery J., Studd J.: "Correlation of urethral physiology and skin collagen in postmenopausal women". *Br. J. Obstet. Gynaecol.*, 1988, 95, 147.
- [29] Sartori M.G.F., Girão M.J.B.C., Simões M.J., Sartori J.P., Baracat E.C., Rodrigues De Lima G.: "Quantitative evaluation of collagen and muscle fibers in the lower urinary tract of castrated and under-hormone replacement female rats". *Clin. Exper. Obstet. Gynecol.*, 2001, 28, 92.

Address reprint requests to:
M. F. SARTORI, M.D.
Av. Onze de Junho, 1006, apt. 51
Vila Clementino
04041-003 São Paulo, SP (Brasil)



CME Journal of Gynecologic Oncology

An International Journal for Continuing Medical Education on Basic and Clinical Gynecologic Oncology

Editor-in-Chief: Péter Bószé

Associate Editor: George D. Wilbanks - Managing Editor: Terézia Barabás

PRIMED-X PRESS - BUDAPEST

Editorial Office: 1301 Budapest, P. O. Box 46, Hungary - Tel./Fax: (36 1) 275 21272

E-mail address: bosze@mail.matav.hu - ISSN: 12199087

PUBLISHED AND FORTHCOMING CHAPTERS

Published Chapters

• Hormone replacement therapy (HRT) and cancer. *Editor William T. Creasman, M.D.* • Techniques of urinary diversion in Gynecologic Oncology. *Editor Javier F. Magrina, M.D.* • Granulosa cell tumors of the ovary. *Editor Péter Bószé, M.D.* • Genetics for Gynecologic Oncologists (part 1). *Editor Péter Bószé, M.D.* • Genetics for Gynecologic Oncologists (part 2). *Editor Péter Bószé, M.D.* • Endodermal sinus tumors (yolk sac tumors) of the ovary. *Editor Peter E. Schwartz, M.D.* • The parametrium and paracolpium. An anatomic and surgical symposium with emphasis on the cardinal ligament as it relates to radical hysterectomy. *Editor C. Paul Morrow, M.D.* • Malignant melanoma of the vulva. *Editor Spyros Retsas, M.D.* • Genetics for Gynecologic Oncologists (part 3). *Editor Péter Bószé, M.D.* • Paclitaxel in breast cancer and gynaecological tumours. *Editor Jan Neijt, M.D.* • Fertility drugs and the risk of gynecological tumours. *Editor Jan Neijt, M.D.* • Current status of intraperitoneal chemotherapy in the management of epithelial ovarian carcinoma. *Editor Murie Markman, M.D.* • Neoadjuvant chemotherapy in the treatment of carcinoma of the uterine cervix. *Editor Guillermo R. di Paola, M.D.* • Stage IIB cervical carcinoma. *Editor Heung-Tat Ng., M.D.* • Teratomas of the ovary. *Editor Péter Bószé, M.D.* • Prognostic factors in epithelial ovarian carcinoma (part 1). *Editor Péter Bószé, M.D.* • Prognostic factors in epithelial ovarian carcinoma (part 2). *Editor Péter Bószé, M.D.* • Cytotoxic drug therapy in gynaecological oncology: principles and practice (part. 2). *Editor Péter Bószé, M.D.* • Cytotoxic drug therapy in gynaecological oncology: principles and practice (part. 3). *Editor Péter Bószé, M.D.* • Prognostic factors in cervical carcinoma (part. 1). *Editor Péter Bószé, M.D.* • Prognostic factors in cervical carcinoma (part. 2). *Editor Péter Bószé, M.D.* • Prognostic factors in cervical carcinoma (part. 3). *Editor Péter Bószé, M.D.* • The place of laparoscopy in the management of gynecologic malignancies. *Editor*

Javier F. Magrina, M.D. • Controversies and new trends in FIGO staging. *Editor John L. Benedet, M.D.* • Global challenge of cervical cancer screening and prevention. *Editor Joseph Monsonogo, M.D.* • Paraaortic nodes: involvement in gynaecological oncology. *Editor Pierluigi Benedetti Panici, M.D.* • New Techniques and assessment of gynaecological tumours. *Editors Harold Fox, M.D. and Michael Wells, M.D.* • Guidelines from the Biomed 2 familial breast cancer demonstration project. "Audit of a new development in medical practice in european centres". *Editors Neva E. Haites, M.D., Iain Brown, PhD, Benedict J. Milner, PhD.* • Cytotoxic drug therapy in gynaecological oncology: principles and practice (part. 1-4). *Editor Péter Bószé, M.D.* • Prognostic factors in cervical carcinoma (part. 1-3). *Editor Péter Bószé, M.D.* • The place of laparoscopy in the management of gynecologic malignancies. *Editor Javier F. Magrina, M.D.* • Controversies and new trends in FIGO staging. *Editor John L. Benedet, M.D.* • Urinary function in relation to and following treatment of gynecologic malignancies. *Editor Péter Bószé, M.D.* • Sertoli-Leydig cell tumors of the ovary. *Editor Maurie Markman, M.D.* • Embryonal carcinoma of the ovary. *Editor Kari J. Syrjänen, M.D.* • Principles of the perioperative management in gynaecological oncology. *Editor Michael Höckel, M.D.* • Elements of bowel surgery as it pertains to gynecologic oncology. *Editor Péter Bószé, M.D.* • Endometriosis and cancer risk. *Editor Farr Nezhat, M.D.*

Forthcoming Chapters

• Fertility drugs, in vitro fertilisation and the risk of gynaecological malignancies. *Editor Curt W. Burger, M.D.* • Current status of fertility sparing treatment in invasive gynecologic malignancies. *Editor Michel Roy, M.D.* • Gynecologic oncology protocols: endometrial cancer. *Editor Péter Bószé, M.D.* • Management of recurrent epithelial ovarian cancer. *Editor Jan B. Vermorken, M.D.* • Ovarian metastases from colorectal cancer. *Editor Niall O'Higgins, M.D.* • Angiogenesis: clinical implications in gynecologic oncology. *Editor Michael Höckel, M.D.*

Obtain the novel approach shaping the future of continuing medical education

The CME Journal of Gynecologic Oncology focuses on controversial issues and new developments in gynecologic oncology with the aim of providing a unique opportunity for those interested in subspecialty training and postgraduate education in gynecologic oncology. The journal is not a venue for original articles, but contains chapters each devoted to a single topic addressed by several internationally acknowledged, exclusively invited experts and edited by an individual distinguished in the field. Practical conclusions and guidelines are given by the Chapter Editor. News, comments, critiques, book reviews and letters are also provided.